820
Views
3
CrossRef citations to date
0
Altmetric
Articles

Analgesic effects of dexmedetomidine and remifentanil on periprocedural pain during percutaneous ablation of renal carcinoma

, , , &
Pages 52-57 | Received 30 Oct 2019, Accepted 19 Jan 2020, Published online: 18 Feb 2020

References

  • Znaor A, Lortet-Tieulent J, Laversanne M, Jemal A, Bray F. International variations and trends in renal cell carcinoma incidence and mortality. Eur Urol. 2015;67:519–30. doi:10.1016/j.eururo.2014.10.002
  • Beland MD, Wolf FJ, Grand DJ, Dupuy DE, Mayo-Smith WW. Incidence of multiple sporadic renal cell carcinomas in patients referred for renal radiofrequency ablation: implications for imaging follow-up. AJR Am J Roentgenol. 2011;197:671–5. doi:10.2214/AJR.10.6044
  • Liu N, Huang D, Cheng X, Chong Y, Wang W, Gan W, et al. Percutaneous radiofrequency ablation for renal cell carcinoma vs. partial nephrectomy: comparison of long-term oncologic outcomes in both clear cell and non-clear cell of the most common subtype. Urol Oncol. 2017;35:530.e1–6. doi:10.1016/j.urolonc.2017.03.014
  • Sommer CM, Stampfl U, Kauczor HU, Pereira PL. Percutaneous radiofrequency ablation of renal tumors: update 2015. Urologe. 2015;54:219–30. doi:10.1007/s00120-014-3672-4
  • Xiaobing W, Wentao G, Guangxiang L, Fan Z, Weidong G, Hongqian G, et al. Comparison of radiofrequency ablation and partial nephrectomy for tumor in a solitary kidney. BMC Urol. 2017;17:79. doi:10.1186/s12894-017-0269-4
  • Acosta Ruiz V, Ladjevardi S, Brekkan E, Häggman M, Lönnemark M, Wernroth L, et al. Periprocedural outcome after laparoscopic partial nephrectomy versus radiofrequency ablation for T1 renal tumors: a modified R.E.N.A.L nephrometry score adjusted comparison. Acta Radiol. 2019;60:260–8. doi:10.1177/0284185118780891
  • Frost EA, Booij LH. Anesthesia in the patient for awake craniotomy. Curr Opin Anaesthesiol. 2007;20:331–5. doi:10.1097/ACO.0b013e328136c56f
  • Jensen MP, Turner JA, Romano JM. What is the maximum number of levels needed in pain intensity measurement?. Pain. 1994;58:387–92. doi:10.1016/0304-3959(94)90133-3
  • Ramsay MA, Savege TM, Simpson BR, Goodwin R. Controlled sedation with alphaxolone-alphadalone. BMJ. 1974;2:656–9. doi:10.1136/bmj.2.5920.656
  • Shamim F, Asghar A, Tauheed S, Yahya M. Radiofrequency ablation of hepatocellular carcinomas: a new spectrum of anesthetic experience at a tertiary care hospital in Pakistan. Saudi J Anaesth. 2017;11:21–5. doi:10.4103/1658-354X.197367
  • Jones CR. Perioperative uses of dexmedetomidine. Int Anesthesiol Clin. 2013;51:81–96. doi:10.1097/AIA.0b013e31828d58c7
  • Beers R, Camporesi E. Remifentanil update: clinical science and utility. CNS Drugs. 2004;18:1085–104. doi:10.2165/00023210-200418150-00004
  • Parashchanka A, Schelfout S, Coppens M. Role of novel drugs in sedation outside the operating room: dexmedetomidine, ketamine and remifentanil. Curr Opin Anaesthesiol. 2014;27:442–7. doi:10.1097/ACO.0000000000000086
  • Borgeat A, Aguirre J. Sedation and regional anesthesia. Curr Opin Anaesthesiol. 2009;22:678–82. doi:10.1097/ACO.0b013e32832f3320
  • Kim HJ, Park BK, Chung IS. Comparison of general anesthesia and conscious sedation during computed tomography-guided radiofrequency ablation of T1a renal cell carcinoma. Can Assoc Radiol J. 2018;69:24–9. doi:10.1016/j.carj.2017.07.003